This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignees: A2a Pharmaceuticals, Inc., Oncocube Therapeutics LLC. Active years: 2023-2024.
Company Filing History:
2 out of 2 
2 out of 2 Years Active: 2023-2024
Title: Burcu Caliskan: Innovator in Cancer Treatment
Introduction
Burcu Caliskan is a prominent inventor based in Ankara, Turkey. She has made significant contributions to the field of cancer treatment through her innovative research and development of novel therapeutic agents. With a total of two patents to her name, Caliskan is recognized for her dedication to advancing medical science.
Latest Patents
Caliskan's latest patents include groundbreaking work on compositions and methods for treating cancer. One of her notable inventions involves inhibitors of TACC, which are designed to treat diseases and disorders related to TACC. Additionally, she has developed a highly potent TACC3 inhibitor, specifically the chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264). This innovative compound targets the TACC3 protein and serves as a mitotic blocker for the treatment of breast cancer and potentially other types of cancer.
Career Highlights
Throughout her career, Caliskan has worked with several notable companies, including A2A Pharmaceuticals, Inc. and Oncocube Therapeutics LLC. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to the development of cutting-edge cancer therapies.
Collaborations
Caliskan has collaborated with esteemed colleagues such as Erden Banoglu and Ozgur Sahin. These partnerships have further enhanced her research and innovation in cancer treatment.
Conclusion
Burcu Caliskan is a trailblazer in the field of cancer research, with her patents reflecting her commitment to finding effective treatments. Her work continues to inspire advancements in medical science and offers hope for patients battling cancer.